What else is made in the USA

No admission : Why Astrazeneca has not yet been vaccinated in the USA

While Astrazeneca's vaccine is used in more than 70 countries around the world, it is still not approved in the United States. As reported by the New York Times, ex-President Donald Trump Astrazeneca pledged 1.2 billion US dollars in May of last year for the development and manufacture of the vaccine. In addition, the manufacturer should supply the United States with 300 million cans.

30 million vaccine doses alone have already been filled in a facility in the state of Ohio, and tens of millions more doses have been produced in a laboratory in Maryland, the newspaper writes. But why is Astrazeneca still not vaccinated in the USA? Why are millions of cans lying around unused?

[If you want to have all the latest news live on your mobile phone, we recommend our completely redesigned app, which you can download here for Apple and Android devices.]

According to the New York Times report, the background is, among other things, that the results of the clinical studies in the USA are not yet available. The British-Swedish company has not yet applied for an emergency approval from the US FDA.

In the fall, work on the study was stopped for almost seven weeks. Astrazeneca was slow to provide the FDA with evidence that the vaccine did not cause serious neurological side effects in two study participants.

The large supply of the vaccine in the US has sparked a discussion in Washington about whether it should not be given to other countries that need it more urgently.

“Other governments are reported to have turned to the US government regarding donations of Astrazeneca cans. We have asked the US government to carefully examine these requests, "the newspaper quoted a company spokesman as saying.

Some health officials in the US have also suggested sending vaccine doses to Brazil, the UK or the EU. EU Council leader Charles Michel recently criticized the US and Great Britain having "imposed a real ban on the export of vaccines or vaccine components".

US government spokeswoman Jen Psaki confirmed that there have been requests from a number of countries for vaccination doses, but the US government has not yet issued any to other states. “So it's not about Europe.” Biden's first duty is to deal with the ongoing crisis in the USA, which is still killing around 1,400 people a day. On Thursday Psaki said: "There are no export bans."

Biden himself said on Wednesday: "If we have a surplus, we will share it with the rest of the world." But he also emphasized: "We will first make sure that the Americans are taken care of first."

Astrazeneca with no advantage over Johnson & Johnson

However, it shouldn't take too long for Astrazeneca to be approved in the USA, as the vaccine doses (as with other manufacturers) only have a limited shelf life. According to the New York Times, it can only be stored for six months at refrigerator temperature.

Meanwhile, the Biden government is trying to order more supplies of the already approved vaccines. These are Johnson & Johnson, Biontech / Pfizer and Moderna.

It is possible that Astrazeneca will ultimately no longer be needed or only be needed for a short time. This has to do with the fact that Astrazeneca doesn't have much advantage over the Johnson & Johnson vaccine. Johnson & Johnson uses a similar technology but only requires one dose of vaccine.

US President Joe Biden has just announced that the staggering according to vaccination groups will be lifted and that vaccines will be released for all adults in the USA by May 1 at the latest. In his first major TV address on Thursday evening, he promised the Americans that they would be able to get together again in small groups and celebrate for Independence Day on July 4th.

In the United States, which has a population of around 330 million, the vaccination campaign is advancing rapidly. According to the CDC health authority, almost one in four adults has now received at least one dose of vaccine. (with dpa)

Now new: We give you 4 weeks of daily mirror plus To home page